 The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks Biotech stocks that hit 52-week highs Dec. 19. Acceleron Pharma Inc NASDAQ: XLRN Ardelyx Inc NASDAQ: ARDX AstraZeneca plc NYSE: AZN Axsome Therapeutics Inc NASDAQ: AXSM priced its 2-million-share common stock offering at 87 per share Clearside Biomedical Inc NASDAQ: CLSD Cortexyme Inc NASDAQ: CRTX Cue Biopharma Inc NASDAQ: CUE Exagen Inc NASDAQ: XGN Globus Medical Inc NYSE: GMED Horizon Therapeutics PLC NASDAQ: HZNP HEALTH SCIENCESSH NASDAQ: IMVT The acquisition vehicle announced merger with Immuvant, a clinical-stage biopharma company focusing on autoimmune disorders IVERIC bio Inc NASDAQ: ISEE Johnson Johnson NYSE: JNJ Barclays upgraded shares to Overweight The Medicines Company NASDAQ: MDCO Merck Co., Inc. NYSE: MRK Mirum Pharmaceuticals Inc NASDAQ: MIRM Momenta Pharmaceuticals, Inc. NASDAQ: MNTA Monopar Therapeutics Inc. NASDAQ: MNPR Went public Thursday Myokardia Inc NASDAQ: MYOK NeoGenomics, Inc. NASDAQ: NEO Novan Inc NASDAQ: NOVN Oramed Pharmaceuticals, Inc. NASDAQ: ORMP Principia Biopharma Inc NASDAQ: PRNB Quest Diagnostics Inc NYSE: DGX Recro Pharma Inc NASDAQ: REPH Sanofi SA NASDAQ: SNY SpringWorks Therapeutics Inc NASDAQ: SWTX Down In The Dumps Biotech stocks that hit 52-week lows Dec. 19. Aethlon Medical, Inc. NASDAQ: AEMD Anixa Biosciences Inc NASDAQ: ANIX Aridis Pharmaceuticals Inc NASDAQ: ARDS China SXT Pharmaceuticals Inc NASDAQ: SXTC Correvio Pharma Corp NASDAQ: ... 